Molmed S.P.A. operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Molmed S.P.A. with three other
miscellaneous service companies in Europe:
Brain Biotechnology Research and Information Network AG
sales of 26.42 million Euro [US$32.69 million]
of which 51%
Veloxis Pharmaceuticals A/S
(196.99 million Danish Kroner [US$32.73 million]
of which 100%
was Pharmaceutical Preparations), and
based in the United Kingdom
(£20.79 million [US$29.53 million]
of which 69%
was Research and development).
Molmed S.P.A. reported sales of 23.00 million Euro (US$28.47 million)
December of 2017.
increase of 18.0%
versus 2016, when the company's sales were 19.48 million Euro.
Sales at Molmed S.P.A. have increased during each of the previous five years
(and since 2012, sales have increased a total of 401%).